Carbetocin was approved by the FDA in 1997 and its heat-stable added to the core list of the EML in 2019 for the prevention of postpartum haemorrhage based on similar effects compared to oxytocin for efficacy and safety outcomes. Heat-stable carbetocin does not require cold chain transport or refrigerated storage thus offering advantages and reducing the risk of quality loss compared to oxytocin in LMICs. Heat-stable carbetocin is promising for LMICs settings.